$CLMT

Wasserstein group (CLMT) discloses 4.6% Calumet Inc. ownership in Schedule 13G/A

Wasserstein Management L.P. and related entities filed an amended Schedule 13G/A for Calumet Inc. reporting beneficial ownership of 3,964,893 shares, or 4.6% of outstanding common stock, as of June 30, 2026. The filing cites 87,147,147 shares outstanding as of May 8, 2026 and lists shared voting and dispositive control among affiliates and individuals.

Original reporting
Published Aug 14, 2026, 8:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 14, 2026, 11:32 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$CLMT
Neutral
medium confidence
Mentioned
$CLMT
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CLMTNeutralLow
01

Why it matters

This is primarily a regulatory disclosure of ownership level and structure. It can inform traders about potential shareholder influence, but the text does not describe an activist agenda, transaction, or operational change.

02

Market read

Traders may use the disclosure to update shareholder maps and watch for follow-on filings, but there is no immediate fundamental catalyst described.

03

What to watch

The filing details shared voting and dispositive power among affiliates and named control persons, which could matter for future governance discussions even without crossing 5%.

Relevance 4/10Novelty 5/10Timing: today’s disclosure of an amended Schedule 13G/A (as of June 30, 2026)

Background

The article summarizes an amended Schedule 13G/A filed by Wasserstein Management L.P. and related entities reporting beneficial ownership in Calumet Inc. as of June 30, 2026.

Company-level read

Ticker impact

$CLMTNeutralMedium confidence
Context

Wasserstein Management discloses an amended Schedule 13G/A showing beneficial ownership of 3,964,893 shares, or 4.6%, in Calumet Inc.

Expected impact

Low likelihood of a sustained move; any reaction is likely limited to short-term sentiment around shareholder activity.

Evidence & confidence

Schedule 13G/A at 4.6% is below the 5% threshold and the text provides no catalyst like a bid, activist campaign, or operational change.

Market effects

Minimal, since the article is a single-filer ownership disclosure with no sector-wide signal.

None indicated.

None indicated.

Counterpoint

A 4.6% holder can still be accumulating quietly; traders may underreact if the filing is the first visible step toward a larger stake.

Key entities

  • Calumet Inc.

    Subject of the Schedule 13G/A ownership disclosure, with beneficial ownership reported at 4.6%.

  • Wasserstein Management L.P.

    Reporting group disclosing beneficial ownership of 3,964,893 shares (4.6%) via affiliated entities and accounts.

  • Rajay Bagaria

    Named control person in the reporting group’s beneficial ownership structure.

  • Joseph Dutton

    Named control person in the reporting group’s beneficial ownership structure.

Related articles

$CLMTMed

S&P upgrades Calumet rating to B- on stronger earnings

S&P Global Ratings upgraded Calumet Inc. to 'B-' from 'CCC+' due to stronger earnings in H1 2026 and improved credit metrics. The company's earnings grew on high margins for specialty oils and renewable fuels. S&P expects adjusted debt to EBITDA of 6x-7x in the next 12 months. Calumet redeemed $100M in senior unsecured notes in July 2026 and plans to expand sustainable aviation fuel production.

$CLMTMedAI 8/10

Calumet (CLMT) Q2 2026 Earnings Call Transcript

Calumet (CLMT) reported Q2 2026 Adjusted EBITDA with Tax Attributes of $175.2 million, driven by Specialty Products and Solutions at $161.7 million. Net loss was $95.9 million, mainly from non-cash RINs expenses of $163.6 million. The company said it repaid $115 million of debt in July, including $100 million note redemption, and discussed SAF expansion and hedges.

$CLMTMed

Why Calumet Stock Is Rocketing Higher Today

Calumet (CLMT) shares rose 15.2% to about $5.99 by 2:36 p.m. ET after a 6.8% drop the prior week. Bank of America kept a buy rating and raised its price target to $45 from $38, citing stronger free cash flow and debt retirement. Calumet reported about $54M free cash flow in Q2 2026 and retired $115M debt in July.

$CLMTMedAI 8/10

CLMT Stock Jumps As Revenue Beats And Debt Falls

Calumet Inc (NASDAQ: CLMT) shares rose about 10.56% after Q2 results and guidance. The company reported Q2 revenue of $1.45B versus a FactSet estimate of $1.12B, with EPS improving to -$1.09 from -$1.70. Operating cash flow was about $92.3M and free cash flow about $54M, alongside $115M debt reduction in July. Goldman Sachs raised its CLMT price target to $40 from $36 but kept a Neutral rating.

$CLMTMed

CLMT Stock Jumps As Revenue Beat Fuels Deleveraging Story

Calumet Inc. (CLMT) shares rose about 10.56% after the company reported Q2 revenue of $1.45B versus $1.12B expected, and narrowed its EPS loss to -$1.09 from -$1.70. The quarter included $54M free cash flow and management cited $115M debt reduction in July, alongside a MaxSAF 150 expansion at Montana Renewables.

$CLMTMed

Why Calumet Stock Flopped on Friday

Calumet (CLMT) shares fell about 6% on Friday after its Q2 earnings showed a surprise net loss. Revenue rose to just under $1.45B, up about 41% YoY, but adjusted net loss was $95.9M, or $1.09/share, versus a year-ago deficit of $147.9M. Analysts expected profit of $0.17/share. Long-term debt exceeded $2.2B.